1.
Expert Rev Hematol
; 14(1): 1-5, 2021 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33280467
Assuntos
COVID-19/epidemiologia , Neoplasias Hematológicas/terapia , Transplante de Células-Tronco Hematopoéticas , Pandemias , SARS-CoV-2 , Centros de Atenção Terciária , Adulto , Aloenxertos , Autoenxertos , Feminino , Neoplasias Hematológicas/epidemiologia , Humanos , Masculino , Pessoa de Meia-Idade , Espanha
2.
Br J Haematol
; 191(3): 386-389, 2020 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32762043
RESUMO
The COVID-19 pandemic has dramatically challenged care for cancer patients, especially those with active treatment who represent a vulnerable population for SARS-CoV-2 infection. Aggressive lymphoid neoplasms, such as diffuse large B cell lymphoma and high-grade B cell lymphoma, need to be treated without delay in order to get the best disease outcome. Because of that, our clinical practice was changed to minimise the risk of SARS-CoV-2 infection while continuing haematological treatment. In this report, we analyse the management of front-line therapy in 18 patients during the COVID-19 outbreak, as well as the results of the implemented measures in their outcome.
